Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 3/20 | 0.34 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.33 |
| ▸ | MET | P08581 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.32 |
| ▸ | MST1R | Q04912 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7673416 | 0.91 | MAP4K4 (0.37) | STK17BMAP3K8MCHR1MAP4K4 | |
| SCHEMBL7663028 | 0.87 | KDR (0.35) | STK17BMCHR1METKDRSORT1 | |
| SCHEMBL7669525 | 0.87 | PDE4B (0.36) | STK17BMAP3K8MCHR1 | |
| SCHEMBL7673525 | 0.87 | RAB9A (0.33) | MAP3K8MCHR1METKDRMST1R | |
| SCHEMBL7667702 | 0.86 | MCHR1 (0.31) | MCHR1 | |
| SCHEMBL7669005 | 0.85 | CNR1 (0.38) | KDM5AMCHR1 | |
| SCHEMBL7671341 | 0.85 | ALDH1A1 (0.42) | MCHR1 | |
| SCHEMBL7664800 | 0.85 | PDE4B (0.38) | MCHR1METKDR | |
| SCHEMBL7669913 | 0.84 | SRC (0.39) | — | |
| SCHEMBL7671184 | 0.84 | CNR1 (0.40) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | STK17B 2060/4885MAP3K8 2852/4885KDM4A 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.